RECRUITING

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.

Official Title

An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Quick Facts

Study Start:2020-01-22

Study Completion:2032-06-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04190862

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Subject ages 18 or older * Subject willing and able to provide informed consent * Subject is medically eligible and have agreed to undergo a fistulotomy * Subject with simple perianal fistula with 2 or fewer fistula tracts * Maximum tract length of 3 inches * Subject without history of Crohn's disease/ Ulcerative Colitis * For female subjects of childbearing potential: * A negative serum or urine pregnancy test at screening is required prior to enrollment * Subject must be willing to use a highly effective method of contraception from the start of the screening period throughout the study period * For males who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception: * Subject must be willing to use a recommended method of contraception and refrain from sperm donation from the start of the conditioning therapy for at least 1 year after completion and discussion with a treating physician	* Concomitant rectovaginal fistulas * Subjects with an abscess * Presence of active infections findings (e.g.; redness, swelling, tenderness or fever) * Presence of rectal and/or anal stenosis * The presence of setons unless removed prior to the treatment * Subjects with ongoing steroid treatment or treated with steroids in the last 4 weeks * Renal impairment defined by creatinine clearance below 90 mL/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN) * Hepatic impairment defined by both of the following laboratory ranges: * Total bilirubin ≥ 1.5 x ULN unless benign congenital hyperbilirubinemia * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2.5 x ULN * Known history of abuse of alcohol or other addictive substances in the 6 months prior to enrollment * Active malignant tumor within 5 years * Current recent history of abnormal, severe, progressive, uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases * Congenital or acquired immunodeficiencies including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) * Major surgery or severe trauma within the previous 6 months * Subjects who are candidates for solid organ transplantation or who may have a high likelihood of needing a solid organ transplant (ex. progressive heart failure) * Females who are who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment * Subjects who have known hypersensitivity or documented allergy to DMSO * Subjects who do not wish to or cannot comply with study procedures * Subjects currently receiving, or having received any investigational drug within 3 months prior to E-CEL UVEC cell therapy

Inclusion Criteria

Exclusion Criteria

* Subject ages 18 or older
* Subject willing and able to provide informed consent
* Subject is medically eligible and have agreed to undergo a fistulotomy
* Subject with simple perianal fistula with 2 or fewer fistula tracts
* Maximum tract length of 3 inches
* Subject without history of Crohn's disease/ Ulcerative Colitis
* For female subjects of childbearing potential:
* A negative serum or urine pregnancy test at screening is required prior to enrollment
* Subject must be willing to use a highly effective method of contraception from the start of the screening period throughout the study period
* For males who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception:
* Subject must be willing to use a recommended method of contraception and refrain from sperm donation from the start of the conditioning therapy for at least 1 year after completion and discussion with a treating physician

* Concomitant rectovaginal fistulas
* Subjects with an abscess
* Presence of active infections findings (e.g.; redness, swelling, tenderness or fever)
* Presence of rectal and/or anal stenosis
* The presence of setons unless removed prior to the treatment
* Subjects with ongoing steroid treatment or treated with steroids in the last 4 weeks
* Renal impairment defined by creatinine clearance below 90 mL/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)
* Hepatic impairment defined by both of the following laboratory ranges:
* Total bilirubin ≥ 1.5 x ULN unless benign congenital hyperbilirubinemia
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2.5 x ULN
* Known history of abuse of alcohol or other addictive substances in the 6 months prior to enrollment
* Active malignant tumor within 5 years
* Current recent history of abnormal, severe, progressive, uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases
* Congenital or acquired immunodeficiencies including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
* Major surgery or severe trauma within the previous 6 months
* Subjects who are candidates for solid organ transplantation or who may have a high likelihood of needing a solid organ transplant (ex. progressive heart failure)
* Females who are who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment
* Subjects who have known hypersensitivity or documented allergy to DMSO
* Subjects who do not wish to or cannot comply with study procedures
* Subjects currently receiving, or having received any investigational drug within 3 months prior to E-CEL UVEC cell therapy

Contacts and Locations

Study Contact

Rohit Rasane

CONTACT

646-962-2789

rkr4004@med.cornell.edu

Ananya Sen

CONTACT

ase4003@med.cornell.edu

Principal Investigator

Jeffrey W Milsom, MD

PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Study Locations (Sites)

Weill Cornell Medical College - NewYork-Presbyterian Hospital

New York, New York, 10065

United States

Collaborators and Investigators

Sponsor: Weill Medical College of Cornell University

Jeffrey W Milsom, MD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-01-22

Study Completion Date2032-06-30

Study Record Updates

Study Start Date2020-01-22

Study Completion Date2032-06-30

Terms related to this study

Additional Relevant MeSH Terms

Anal Fistula